Company Aggregate Debt: fulgentgenetics.com (FLGT)

Fulgent Genetics, Inc. (FLGT) specializes in DNA analysis and laboratory diagnostics, where profitability relies on the demand for cancer screenings and insurance approval of tests. The business is currently pivoting toward the acquisition of digital pathology assets, leveraging capital generated from previous pandemic-related research. The stock price trend demonstrates stability due to AI-driven cost optimization and a lack of debt, while the separate_debt metric stands at 0.01.

This metric reflects the total volume of borrowed funds used to scale the operational activities of Fulgent Genetics, Inc. (FLGT). Investors should evaluate the balance between financial leverage and the business's solvency. By analyzing the trend of total liabilities, one can determine the company's degree of dependence on external capital. Debt dynamics demonstrate the efficiency of investments in laboratory robotization, which is critical for maintaining high throughput in genetic sequencing.